Topic: acute lymphoblastic leukemia
Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing assays as it moves its blood cancer drugs toward approval.
Fresh from reporting clinical data at ASH, Immunochina has raised $20 million to speed up its CAR-T development programs.
Servier picked up Asparlas in its $2.4 billion buyout of Shire's oncology unit.
Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Since launch, Allogene has gained a new CFO and raised another $120 million. Now, it is looking to raise up to $100 million in its IPO.
A drug that blocks heat shock protein 90 (HSP90) offer a new way of treating an aggressive form of leukemia.
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.